ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,949.17
-0.60%
US Tech 100
20,266.80
-1.09%
다우존스 지수
43,750.86
-0.47%
Bitcoin
88,326.85
1.12%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Tempest Therpeutics Inc (TPST) 시세

Tempest Therpeutics Inc

Tempest Therpeutics Inc (TPST)

NASDAQ
0.9701
0.0035
(0.36%)
마감 15 11월 6:00AM
15분 지연
0.95
-0.0201
(-2.07%)
시간외 거래: 9:56AM
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
0.95
매수가
0.949
매도가
0.95
거래량
1,532,561
0.9695 일간 변동폭 1.03
0.8637 52주 범위 6.00
market_cap
23.947M
전일 종가
0.9666
개장가
0.9701
최근 거래 시간
100
@
0.95
(formt)
마지막 거래 시간
재정 규모
US$ 1,527,199
VWAP
0.996502
평균 볼륨(3m)
3,265,787
발행 주식
25,207,792
배당수익률
-
주가수익률
-0.83
주당순이익(EPS)
-1.17
매출
-
순이익
-29.49M

Tempest Therpeutics Inc 정보

Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.tempesttx.com
본부
Wilmington, Delaware, USA
설립됨
-
Tempest Therpeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker TPST. The last closing price for Tempest Therpeutics was US$0.97. Over the last year, Tempest Therpeutics shares have traded in a share price range of US$ 0.8637 to US$ 6.00.

Tempest Therpeutics currently has 25,207,792 shares in issue. The market capitalisation of Tempest Therpeutics is US$24.37 million. Tempest Therpeutics has a price to earnings ratio (PE ratio) of -0.83.

TPST 최신 뉴스

추가 뉴스

Form DEF 14A - Other definitive proxy statements

13 11월 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

13 11월 2024
Edgar (US Regulatory)

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced...

13 11월 2024
GlobeNewswire Inc.

Form 8-K - Current report

13 11월 2024
Edgar (US Regulatory)

Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma

BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

12 11월 2024
GlobeNewswire Inc.

Form PRE 14A - Other preliminary proxy statements

30 10월 2024
Edgar (US Regulatory)

Form 8-A12B/A - Registration of securities [Section 12(b)]: [Amend]

10 10월 2024
Edgar (US Regulatory)

Form 8-K - Current report

10 10월 2024
Edgar (US Regulatory)

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...

10 10월 2024
GlobeNewswire Inc.

Tempest Extends Limited Duration Stockholder Rights Plan

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or the “Company”), a clinical-stage biotechnology company developing first-in-classi...

10 10월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.1-9.523809523811.051.160.936226628501.05329512CS
4-0.17-15.17857142861.121.210.863736753581.05819006CS
12-0.54-36.24161073831.491.590.863732657871.10532409CS
26-2.3-70.76923076923.253.64990.863729703111.39925881CS
52-2.6-73.23943661973.5560.863720221632.09227936CS
156-10.43-91.652021089611.3811.980.1716020274.3648622CS
260-12.86-93.120926864613.81410.1714676724.8854102CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
MTEMMolecular Templates Inc
US$ 0.60
(86.28%)
331.49M
QUBTQuantum Computing Inc
US$ 4.43
(66.54%)
228.27M
OMEROmeros Corporation
US$ 6.96
(66.11%)
14.19M
ADGMAdagio Medical Holdings Inc
US$ 3.71
(57.87%)
2.65M
VVPRVivoPower International PLC
US$ 1.18
(50.47%)
5.91M
SOWGSow Good Inc
US$ 4.23
(-56.88%)
2.88M
WCTWellchange Holdings Company Limited
US$ 4.08
(-48.35%)
1.27M
NVCTNuvectis Pharma Inc
US$ 5.73
(-46.30%)
1.63M
KXINKaixin Holdings
US$ 2.525
(-39.59%)
4.47M
TRNRInteractive Strength Inc
US$ 3.59
(-38.42%)
1.23M
ELABElevai Labs Inc
US$ 0.024658
(-0.17%)
1.79B
XTIAXTI Aerospace Inc
US$ 0.0565
(-1.22%)
363.98M
MTEMMolecular Templates Inc
US$ 0.60
(86.28%)
331.49M
SVMHSRIVARU Holding Ltd
US$ 0.0268
(10.74%)
245.93M
QUBTQuantum Computing Inc
US$ 4.43
(66.54%)
228.27M

TPST Discussion

게시물 보기
georgie18 georgie18 3 일 전
TPST...$1.09...🥳...BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that the company received a “Study May Proceed” letter from the U.S. Food and Drug Administration (FDA) to evaluate amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab, the current standard of care, versus the standard of care alone in a pivotal randomized Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC).

“The clinical and regulatory team at Tempest are thrilled to receive this notice from FDA with respect to the planned pivotal Phase 3 trial to evaluate amezalpat as a potential treatment for first-line liver cancer,” said Sam Whiting M.D., Ph.D., chief medical officer and head of R&D of Tempest. “Previously reported positive Phase 2 data underscore amezalpat’s potential to improve the survival of patients facing this life-threatening disease, and our team is dedicated to advancing the program and bringing amezalpat to patients.”

georgie18

Member Level
Re: None

Friday, November 08, 2024 6:22:34 PM

Post#
664322
of 664538
TPST...$1.09...Chart firming up from the .85 Range Bottom...R/S coming here...🥳
👍️0
aBeezlee aBeezlee 4 일 전
I sold my shares, but kept the calls.
👍️0
georgie18 georgie18 6 일 전
TPST...$1.09...Chart firming up from the .85 Range Bottom...R/S coming here...🥳
👍️0
aBeezlee aBeezlee 1 주 전
Not a bad recovery. Will see if an ER or business report is released, then decide to sell or not.
👍️0
Monksdream Monksdream 2 주 전
TPST , new 52 week low
👍️0
stockyupydowny stockyupydowny 2 주 전
Agreed, we will see positive news and a boost in price prior to the split..... the higher the price the lower the split IF its even required. Should they get positive news and more support from ROCHE this can rocket and then cancel split... that's moon time!
👍️ 1
georgie18 georgie18 2 주 전
We shall see...🥳
👍️0
aBeezlee aBeezlee 2 주 전
1 to 2, or 1 to 15 RS. The split doesn't make sense unless a notable event is coming. Negative sentiment will simply beat it down, and kill existing holders further.

I'm under the impression dilution is coming.
👍️0
georgie18 georgie18 2 주 전
Yes I did...will buy back when the dust settles...🥳...made great profit with TPST and if the reverse should happen it should put this stock in the $40...imo...we shall see...
👍 1
rocketeer357 rocketeer357 2 주 전
Did you sell on the 14a news?
👍️0
georgie18 georgie18 2 주 전
You saw the 14a...🥳
👍️0
The GidDy uP Kid The GidDy uP Kid 2 주 전
aDDed after hours sub $1 range...
👍️0
aBeezlee aBeezlee 2 주 전
RS was unexpected for something without a delisting notice. Perhaps something planned to prevent a takeover. Hmm...
👍️0
georgie18 georgie18 2 주 전
TPST...14A Filing...Approval of a series of alternate amendments to our Restated Certificate of Incorporation to effect, at the option of our Board of Directors, a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-15, inclusive, with such ratio to be determined by our Board of Directors in its sole discretion (“Reverse Stock Split Proposal” or “Proposal 1”).
What if another matter is properly brought before the Special Meeting?
👍 1
georgie18 georgie18 2 주 전
TPST....85...A/H Dip...🥳
👍️0
georgie18 georgie18 2 주 전
Nice to have you with me on it...🥳
👍️0
tw0122 tw0122 2 주 전
One of your GM favorites been adding myself low $1s for next blastoff to $2s ...newsand trials
👍️0
georgie18 georgie18 2 주 전
TPST...$1.16s in the P/M...🥳

georgie18

Member Level
Re: georgie18 post# 614

Friday, October 25, 2024 12:38:28 PM

Post#
615
of 617
TPST...$1.12s clearing here...🥳Reversing...

georgie18

Member Level
Re: georgie18 post# 662364

Friday, October 25, 2024 9:43:40 AM

Post#
662715
of 662771
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
👍️0
aBeezlee aBeezlee 3 주 전
Long hold. Roche wouldn't supply them with goods if they felt phase 3 would fail. Looking for $2 on positive results.
👍️0
georgie18 georgie18 3 주 전
Have a Great Weekend Y'all...🥳
👍️0
georgie18 georgie18 3 주 전
TPST...$1.12s clearing here...🥳Reversing...

georgie18

Member Level
Re: georgie18 post# 662364

Friday, October 25, 2024 9:43:40 AM

Post#
662715
of 662771
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
👍️0
georgie18 georgie18 3 주 전
TPST...$1.08...Big Block Buys hitting here...🥳

georgie18

Member Level
Re: None

Wednesday, October 23, 2024 8:55:30 AM

Post#
613
of 613
TPST...Loaded $1.03 to $1.05s...🥳
👍️0
georgie18 georgie18 3 주 전
TPST...Loaded $1.03 to $1.05s...🥳
👍️0
Xunefox Xunefox 4 주 전
May be an AH show after all
👍️0
aBeezlee aBeezlee 4 주 전
Yup TPST! I have RNAZ on list too. Buying both with next check. 🔥
👍️0
georgie18 georgie18 4 주 전
TPST...$1.22...🥳...Dipping it to fill the Open Gap...another great add spot...Ran to $1.60 range in the A/H ...

georgie18

Member Level
Re: georgie18 post# 384329

Tuesday, October 15, 2024 3:37:36 PM

Post#
384411
of 384426
TPST...$1.14clearing here...🥳

georgie18

Member Level
Re: None

Friday, October 11, 2024 9:46:27 AM

Post#
603
of 603
TPST...99...great add spot....🥳
👍️0
georgie18 georgie18 4 주 전
TPST …yes beauty move in the A/H…🥳
👍️0
Vitamin310 Vitamin310 4 주 전
I’m in!
👍️0
Money hunt Money hunt 4 주 전
TPST smell green dude!!! RNAZ Next DRUG
👍️0
The GidDy uP Kid The GidDy uP Kid 1 월 전
Nice Georgie… TPST $1.61 after hours close…
👍️0
aBeezlee aBeezlee 1 월 전
The next DRUG?!
👍️0
georgie18 georgie18 1 월 전
TPST...$1.14clearing here...🥳

georgie18

Member Level
Re: None

Friday, October 11, 2024 9:46:27 AM

Post#
603
of 603
TPST...99...great add spot....🥳
👍️0
georgie18 georgie18 1 월 전
TPST...99...great add spot....🥳
👍️0
Invest-in-America Invest-in-America 1 월 전
TPST: Nope!! Cancer is NOT trending anymore, CLOWN!!! (Nice call, IDIOT!!!)
👍️0
georgie18 georgie18 1 월 전
TPST...$1.09...Great add opportunity...imo...we shall see...🥳
👍️0
georgie18 georgie18 1 월 전
TPST...$1.59...from the .90 range bottom...🥳BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.

georgie18

Member Level
Re: None

Friday, August 09, 2024 2:43:01 PM

Post#
652989
of 660804
TPST...$1.16...Taking a hit on earnings...adding more down here...🥳
👍️0
TrendTrade2016 TrendTrade2016 1 월 전
july shelf offering allows lender to sell stock at anytime
👍️0
Invest-in-America Invest-in-America 1 월 전
TPST: Hopefully!! (But is "Cancer" TRENDING anymore??)
👍️0
tw0122 tw0122 1 월 전
TPST 1.82 +’35% resistance at 1.85 looks good again until 2.01- 2.23 resistance then big jump to 2.91

a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.
Under the agreement, Roche will supply atezolizumab globally and Tempest will sponsor and lead the pivotal study. This agreement builds on a clinical collaboration between the companies pursuant to which amezalpat was combined with atezolizumab and bevacizumab in first-line HCC patients and compared to atezolizumab and bevacizumab alone in a randomized Phase 1b/2 study. Tempest retains all development and commercial rights to amezalpat.
👍️0
Invest-in-America Invest-in-America 1 월 전
TPST: I'm in!! Are you?? (Heck, goin' to Phase-3 with Roche?? I'll jump-on for ride!!)

👍️0
Invest-in-America Invest-in-America 1 월 전
TPST: Some Roche agreement news.
👍️0
georgie18 georgie18 2 월 전
TPST...$1.44s clearing on the 50MA Break...🥳
👍️0
georgie18 georgie18 2 월 전
TPST...$1.50s clearing into the close...🥳
👍️0
georgie18 georgie18 2 월 전
Have a Great Weekend Y'all...🥳
👍️0
georgie18 georgie18 2 월 전
Nice...will be very pleased with 1/2 that target...🥳
👍️0
glens0 glens0 2 월 전
Bought a starter today.
DJ Tempest Therapeutics Price Target Maintained With a $47.00/Share by HC Wainwright & Co.
12:54 PM ET 8/15/24 | Dow Jones
👍️0
georgie18 georgie18 2 월 전
TPST...$1.35...🥳
👍️0
georgie18 georgie18 3 월 전
TPST...$1.44...HOD...🥳
👍️0
georgie18 georgie18 3 월 전
TPST...$1.50...Off the .90 range dip...🥳...was $6 recently...setting up for a Breakout...imo...we shall see...
👍️0
georgie18 georgie18 3 월 전
TPST...1.4995...HOD...Beauty move off the .90 range dip...🥳Was $6 a couple of months ago...🥳
👍️0

최근 히스토리

NASDAQ
TPST
Tempest Therpeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유